• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

川崎病:意大利儿科学会指南,第二部分——抵抗形式和心血管并发症的治疗、随访、生活方式和心血管风险预防。

Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

机构信息

Bambino Gesù Children's Hospital, Piazza S. Onofrio n. 4, 00165, Rome, Italy.

Università Cattolica Sacro Cuore, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.

出版信息

Ital J Pediatr. 2018 Aug 30;44(1):103. doi: 10.1186/s13052-018-0529-2.

DOI:10.1186/s13052-018-0529-2
PMID:30157893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6116479/
Abstract

This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations.Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications.

摘要

本实用指南第二部分与川崎病(KD)相关,旨在帮助及时诊断和最适当治疗 KD 抵抗型和心血管并发症,包括非药物治疗、随访、生活方式和长期预防心血管风险,共提出 17 条推荐意见。然而,指南不应被视为限制儿科医生和临床医生治疗选择的规范,因为根据特殊医疗情况、患者状况、疾病严重程度或个体并发症,可能需要采用指南推荐以外的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f73/6116479/41ee03b8a06a/13052_2018_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f73/6116479/97636eb0b671/13052_2018_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f73/6116479/41ee03b8a06a/13052_2018_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f73/6116479/97636eb0b671/13052_2018_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f73/6116479/41ee03b8a06a/13052_2018_529_Fig2_HTML.jpg

相似文献

1
Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.川崎病:意大利儿科学会指南,第二部分——抵抗形式和心血管并发症的治疗、随访、生活方式和心血管风险预防。
Ital J Pediatr. 2018 Aug 30;44(1):103. doi: 10.1186/s13052-018-0529-2.
2
Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase.川崎病:意大利儿科学会指南,第一部分-定义、流行病学、病因发病机制、急性期临床表现和治疗。
Ital J Pediatr. 2018 Aug 30;44(1):102. doi: 10.1186/s13052-018-0536-3.
3
A national survey on the pediatric cardiologist's clinical approach for patients with Kawasaki disease.一项关于儿科心脏病专家对川崎病患者临床治疗方法的全国性调查。
Pediatr Cardiol. 2002 Nov-Dec;23(6):639-46. doi: 10.1007/s00246-001-9070-x.
4
Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications.川崎病药物治疗及其心血管并发症管理的当前建议。
Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):301-8.
5
Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.川崎病静脉注射免疫球蛋白抵抗的生物标志物与冠状动脉病变。
World J Pediatr. 2019 Apr;15(2):168-175. doi: 10.1007/s12519-019-00234-6. Epub 2019 Feb 27.
6
Kawasaki disease: part II. Complications and treatment.川崎病:第二部分。并发症和治疗。
J Am Acad Dermatol. 2013 Oct;69(4):513.e1-8; quiz 521-2. doi: 10.1016/j.jaad.2013.06.040.
7
[Kawasaki disease: what you need to know].[川崎病:你需要了解的内容]
Arch Pediatr. 2012 Nov;19(11):1264-8. doi: 10.1016/j.arcped.2012.07.005. Epub 2012 Aug 24.
8
The many faces of Kawasaki syndrome.川崎病的多种表现
Hosp Pract (1995). 2000 Jan 15;35(1):77-81, 85-6, 91-4. doi: 10.3810/hp.2000.01.182.
9
A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?川崎病急性期静脉注射免疫球蛋白治疗的回顾性队列研究:是否越早越好?
Cardiovasc Ther. 2021 Jun 18;2021:6660407. doi: 10.1155/2021/6660407. eCollection 2021.
10
Cardiovascular involvement in Kawasaki disease.川崎病的心血管受累情况。
Indian Pediatr. 2005 Sep;42(9):918-22.

引用本文的文献

1
MIS-C, inherited metabolic diseases and methylmalonic acidemia: a case report and review of the literature.儿童多系统炎症综合征、遗传性代谢疾病与甲基丙二酸血症:一例病例报告及文献综述
Ital J Pediatr. 2025 Jul 1;51(1):202. doi: 10.1186/s13052-025-02052-1.
2
[Interpretation of similarities and differences in Kawasaki disease guidelines at home and abroad].[国内外川崎病诊疗指南异同解读]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Feb 15;27(2):144-147. doi: 10.7499/j.issn.1008-8830.2406041.
3
Utilizing T-Lymphocyte Activation-Related Cytokines to Predict Non-Responsiveness to Treatment in Pediatric Kawasaki Disease.

本文引用的文献

1
New mosaic tiles in childhood hereditary autoinflammatory disorders.儿童遗传性自体炎症性疾病中的新马赛克皮损。
Immunol Lett. 2018 Jan;193:67-76. doi: 10.1016/j.imlet.2017.11.013. Epub 2017 Dec 1.
2
Myocarditis and Kawasaki disease.心肌炎和川崎病。
Int J Rheum Dis. 2018 Jan;21(1):45-49. doi: 10.1111/1756-185X.13219. Epub 2017 Nov 3.
3
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.川崎病的诊断、治疗和长期管理:美国心脏协会发布的一份面向医疗保健专业人员的科学声明。
利用T淋巴细胞活化相关细胞因子预测小儿川崎病治疗无反应性
Pediatric Health Med Ther. 2024 Dec 17;15:375-383. doi: 10.2147/PHMT.S489512. eCollection 2024.
4
A Comparison of Kawasaki Disease during the SARS-CoV-2 Pandemic with Multisystem Inflammatory Syndrome in Children.2019冠状病毒病大流行期间川崎病与儿童多系统炎症综合征的比较
Children (Basel). 2024 Sep 28;11(10):1185. doi: 10.3390/children11101185.
5
Cardiovascular involvement in children with COVID-19 temporally related multisystem inflammatory syndrome (MIS-C): can cardiac magnetic resonance arrive to the heart of the problem?儿童 COVID-19 相关多系统炎症综合征(MIS-C)中的心血管受累:心脏磁共振能否直击问题核心?
Ital J Pediatr. 2024 May 3;50(1):91. doi: 10.1186/s13052-024-01658-1.
6
Dilemma in diagnosing incomplete Kawasaki disease in a resource limited setting.在资源有限的情况下诊断不完全川崎病的困境。
Ann Med Surg (Lond). 2023 Oct 2;85(11):5809-5812. doi: 10.1097/MS9.0000000000001380. eCollection 2023 Nov.
7
Comparison of Demographic, Clinical, and Echocardiographic Features Between Complete and Incomplete, and Early and Late Presenters of Kawasaki Disease: A 10-Year Single-Center Experience.川崎病完全型与不完全型、早发型与晚发型患者的人口统计学、临床及超声心动图特征比较:一项为期10年的单中心经验
Cureus. 2023 Sep 23;15(9):e45819. doi: 10.7759/cureus.45819. eCollection 2023 Sep.
8
Two cases of Kawasaki disease: Clinical characteristics and onset of fever and gastrointestinal symptoms.两例川崎病:临床特征和发热及胃肠道症状的发病情况。
Immun Inflamm Dis. 2023 Jul;11(7):e929. doi: 10.1002/iid3.929.
9
An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children.川崎病非典型表现报告及静脉注射免疫球蛋白无反应儿童识别的最新进展
Diagnostics (Basel). 2023 Apr 17;13(8):1441. doi: 10.3390/diagnostics13081441.
10
Ten-month follow-up of patients with covid-19 temporally related multi-system inflammatory syndrome in children: the experience of the children hospital of Palermo.新冠病毒相关儿童多系统炎症综合征患者的 10 个月随访:巴勒莫儿童医院的经验。
Ital J Pediatr. 2023 Mar 23;49(1):37. doi: 10.1186/s13052-023-01416-9.
Circulation. 2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29.
4
A master role for neutrophils in Kawasaki syndrome.中性粒细胞在川崎病中的主要作用。
Immunol Lett. 2017 Apr;184:112-114. doi: 10.1016/j.imlet.2017.02.011. Epub 2017 Feb 17.
5
A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.自身炎症性综合征的系统方法:给初学者的拼写手册。
Expert Rev Clin Immunol. 2017 Jun;13(6):571-597. doi: 10.1080/1744666X.2017.1280396. Epub 2017 Feb 1.
6
Management of coronary artery aneurysms using abciximab in children with Kawasaki disease.在川崎病患儿中使用阿昔单抗治疗冠状动脉瘤
Int J Cardiol. 2016 Oct 1;220:65-9. doi: 10.1016/j.ijcard.2016.06.062. Epub 2016 Jun 20.
7
Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.英夫利昔单抗在川崎病治疗中是个新事物:一项来自印度北部的为期8年的单中心研究。
Clin Exp Rheumatol. 2016 May-Jun;34(3 Suppl 97):S134-8. Epub 2016 Apr 15.
8
Monoclonal antibody therapy for Kawasaki disease: a protocol for systematic reviews and meta-analysis.川崎病的单克隆抗体治疗:系统评价与荟萃分析方案
Syst Rev. 2016 Apr 12;5:60. doi: 10.1186/s13643-016-0236-2.
9
Kawasaki Disease.川崎病。
J Am Coll Cardiol. 2016 Apr 12;67(14):1738-49. doi: 10.1016/j.jacc.2015.12.073.
10
The Spectrum of Cardiovascular Lesions Requiring Intervention in Adults After Kawasaki Disease.川崎病后成人需要介入干预的心血管病变谱。
JACC Cardiovasc Interv. 2016 Apr 11;9(7):687-96. doi: 10.1016/j.jcin.2015.12.011.